Acta Dermato-Venereologica 99-6CompleteContent | Page 23
616
SHORT COMMUNICATION
Economic Analysis of Herpes Zoster in a Hospital Setting in Hong Kong
Wai-kit MING 1,2 , Wing-yin YU 1 , Owen Tak-yin TSANG 3 , Paul Kay-sheung CHAN 4 and Joyce Hoi-sze YOU 1
School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, 2 Harvard Medical School, Harvard
University, Boston, Massachusetts, USA, 3 Department of Medicine & Geriatrics, The Princess Margaret Hospital, Hospital Authority, and
4
Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong. E-mail: [email protected]
1
Accepted Jan 16, 2019; E-published Jan 17, 2019
Both old age and female sex are well-recognized risk
factors in herpes zoster (HZ), and the rate of HZ-related
hospitalization is also associated with age (1, 2). Hospi-
talization costs in Taiwan in 2006 were estimated as USD
1,427 per case of HZ (3). More than 50% of the Hong Kong
population are female and 40% are 50 years or older (4).
With an ageing population, the disease burden of HZ in
Hong Kong is expected to increase.
Zoster vaccine is reported to be effective and safe in pre-
venting HZ in adults aged 50 years and above (5, 6), yet it is
not included in the current public vaccination programme in
Hong Kong. The direct medical cost of treatment of patients
hospitalized with HZ is a crucial factor in examining the
potential health economic benefits of zoster vaccine against
HZ incidence and HZ-related hospitalization. The present
study therefore analysed the direct medical costs of HZ in
older adult patients in the hospital setting.
METHODS
using backward stepwise logistic models. The odds ratios with
95% confident interval (OR 95% CI) of significant predictors on
high cost were reported. A p-value < 0.05 was considered statis-
tically significant.
RESULTS
A total of 105 cases was reviewed, and 15 (14%) were
immunocompromised patients (Table I). The age of im-
munocompromised (64 ± 10 years) and immunocompetent
(71 ± 11 years) patients were not significantly different.
Of 15 immunocompromised patients, use of immune-
suppressant/high-dose corticosteroid was the common
underlying cause.
The incidence of HZ-related complication (≥ 1 com-
plication) was high in both immunocompromised (67%)
and immunocompetent (43%) patients. Comparing with
immunocompetent cases, higher rates of disseminated HZ
(7% vs. 0%; p = 0.01) and HZ-related nervous system com-
plications (13% vs. 1%; p = 0.009) occurred in the immu-
nocompromised group. The hospital LOS was also longer
in immunocompromised patients (14.7 ± 14.3 days) than in
the immunocompetent group (5.9 ± 7.9 days) (p < 0.001).
The mean total direct medical cost of hospitalized cases
(n = 105) was USD 4,883 ± 6,271 (USD 1=HKD 7.8). The
A retrospective observational study was conducted in 2 tertiary
hospitals of Hong Kong. Patients aged 50 years or older with
discharge diagnosis of HZ during the period between 1 January
2011 and 31 December 2013 were included. Patient demographics
and utilization of healthcare resources for HZ were retrieved
from medical records. The resource items were hospital
length of stay (LOS), diagnostic tests, drug treatment for
Table I. Patient demographics, zoster-related complications and direct
HZ and HZ-related complications. The study protocol
cost for hospitalized cases of herpes zoster (HZ)
was approved by the Joint Chinese University of Hong
Immuno
Immuno
Kong–New Territories East Cluster Clinical Research
All patients compromised competent
Ethics Committee and the Kowloon West Cluster Clinical
(n = 105)
(n = 15)
(n = 90)
p-value a
Research Ethics Committee.
Age, years, mean ± SD
70.2 ± 11.4
64.3 ± 10.0
71.2 ± 11.4
0.63
The cost analysis was conducted with 2018 costs from
Male, n (%)
50 (47.6)
8 (53)
42 (47)
0.03
the perspective of the public healthcare provider in Hong
Comorbidity, n (%)
Cardiovascular disease b
68 (64.8)
10 (67)
58 (64)
0.87
Kong. The Hospital Authority is non-profit making and
Diabetes mellitus
29 (27.6)
3 (20)
26 (29)
0.48
subsidized by the government, and the hospitalization
7 (6.7)
1 (7)
6 (7)
1.00
Respiratory disease c
charge billed to non-Hong Kong residents was therefore
Herpes zoster (HZ) complication, n (%)
assumed to represent the cost of healthcare services. The
One or more complication(s)
49 (47)
10 (67)
39 (43)
0.09
daily charges to non-Hong Kong residents for the general
Post-herpetic neuralgia
41 (39)
8 (53)
33 (37)
0.22
medical ward (USD 654 per day) and intensive care unit
HZ ophthalmicus
7 (7)
0 (0)
7 (8)
0.26
(USD 3,128 per day) were found in the Fees and Charges
Disseminated HZ
1 (1)
1 (7)
0 (0)
0.01
Nervous system
3 (3)
2 (13)
1 (1)
0.009
list (7), and the unit cost of medication and laboratory tests
Ramsay Hunt syndrome
2 (2)
1 (7)
1 (1)
0.15
were obtained from the study hospitals.
Meningitis encephalitis
1 (1)
1 (7)
0 (0)
0.01
Data analysis was conducted with Microsoft Excel 2017
Length of stay, days, mean ± SD 7.1 ± 9.5
14.7 ± 14.3
5.9 ± 7.9
< 0.001
(Microsoft Corporation, Redmond, USA) and SPSS 16.0
Cost (USD) d , mean ± SD
(SPSS Inc., Chicago, USA) for Windows. Continuous va-
Laboratory
38 ± 66
46 ± 66
37 ± 66
0.63
riables were compared by analysis of variance (ANOVA),
Medication
55 ± 85
69 ± 121
41 ± 71
< 0.001
Hospitalization
4,792 ± 6,236 9,713 ± 9,355 3,971 ± 5,187 < 0.001
and Pearson’s χ 2 test was used for comparison of binary
Total direct medical cost
4,883 ± 6,271 9,891 ± 9,383 4,049 ± 5,212 < 0.001
variables. To determine predictors of high treatment cost
a
(defined as ≥ 75 th percentile of total direct medical cost),
p-value for comparison of immunocompromised group vs. immunocompetent group.
b
Cardiovascular diseases included congestive heart failure, dyslipidaemia, hypertension,
univariate analysis was performed on demographic and
ischaemic heart disease and atrial fibrillation. c Respiratory diseases included pneumonia,
clinical factors (with frequency ≥ 5%). The factors with
acute bronchitis, acute exacerbation of underlying chronic respiratory conditions, pneumonitis,
potential association (p ≤ 0.1) were further investigated
respiratory failure and pneumothorax. d USD 1= HKD 7.8.
doi: 10.2340/00015555-3118
Acta Derm Venereol 2019; 99: 616–617
This is an open access article under the CC BY-NC license. www.medicaljournals.se/acta
Journal Compilation © 2019 Acta Dermato-Venereologica.